Bioway Inc., is a novel drug development company that develops blood cancer treatments based on PI3K-  delta inhibitor and NASH treatments based on SIRT1 activator. We have confirmed Best-in-Class in the fast-  growing blood cancer market (CAGR of 11% or more) and expected to achieve First-in-Class status in the  NASH treatment market as well (CAGR 64% or more). We have published AACR Chicago 2018 a poster based  on pre-clinical results. We are actively engaged in business for license out (L/O). In relation to blood cancer  development, Bioway Inc., has been selected for specialized investment and clinical support projects for new  drug development by the Ministry of Health and Welfare.